Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Cancer. 2016 Aug 1;122(23):3650–3656. doi: 10.1002/cncr.30231

Figure 1.

Figure 1

Hyper-CVAD + ponatinib and hyper-CVAD + dasatinib after propensity score matching: a) event-free survival, b) overall survival. The 3-year EFS rates of hyper-CVAD + ponatinib and hyper-CVAD + dasatinib were 69% and 46%, respectively (p=0.04), and the 3-year OS rates were 83% and 56%, respectively (p=0.03).